Payment overview · 2025
General Payments
$165.24
9 reported records · 7 companies
Healthcare provider profile · identity verified
Williams Bradley Burrows, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · MT PLEASANT, TX · NPI 1114924867
Verified facts
What the public records show
CMS Open Payments records show Williams Bradley Burrows, D.O. received $165.24 in general payments during 2025 across 9 reported records.
Axsome Therapeutics, Inc. accounted for 25.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $41.45 | 25.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.33 | 22.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.59 | 13.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.75 | 11.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.04 | 9.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.21 | 9.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.87 | 8.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $165.24 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $41.45 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.33 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.59 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
70 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 654 | 189 |
| Levothyroxine Sodium | Levothyroxine Sodium | 593 | 152 |
| Losartan Potassium | Losartan Potassium | 525 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 479 | 137 |
| Gabapentin | Gabapentin | 422 | 115 |
| Pantoprazole Sodium | Pantoprazole Sodium | 411 | 122 |
| Meloxicam | Meloxicam | 317 | 84 |
| Metformin Hcl Er | Metformin Hcl | 271 | 66 |
| Lisinopril | Lisinopril | 254 | 72 |
| Azithromycin | Azithromycin | 249 | 172 |
| Metoprolol Succinate | Metoprolol Succinate | 220 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 217 | 61 |
| Potassium Chloride | Potassium Chloride | 212 | 68 |
| Famotidine | Famotidine | 210 | 70 |
| Furosemide | Furosemide | 202 | 55 |
| Ozempic | Semaglutide | 197 | 41 |
| Prednisone | Prednisone | 197 | 135 |
| Clopidogrel | Clopidogrel Bisulfate | 178 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 172 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 53 |
| Omeprazole | Omeprazole | 161 | 43 |
| Trazodone Hcl | Trazodone Hcl | 161 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 157 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 147 | 40 |
| Simvastatin | Simvastatin | 147 | 39 |
| Carvedilol | Carvedilol | 136 | 38 |
| Metformin Hcl | Metformin Hcl | 135 | 41 |
| Glimepiride | Glimepiride | 131 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 38 |
| Montelukast Sodium | Montelukast Sodium | 122 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 63 |
| Eliquis | Apixaban | 111 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 109 | 47 |
| Allopurinol | Allopurinol | 106 | 34 |
| Sertraline Hcl | Sertraline Hcl | 88 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 19 |
| Finasteride | Finasteride | 73 | 20 |
| Donepezil Hcl | Donepezil Hcl | 72 | 18 |
| Ezetimibe | Ezetimibe | 70 | 18 |
| Synthroid | Levothyroxine Sodium | 70 | 18 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 65 | 53 |
| Pioglitazone Hcl | Pioglitazone Hcl | 65 | 25 |
| Celecoxib | Celecoxib | 62 | 18 |
| Sucralfate | Sucralfate | 62 | 24 |
| Cefuroxime | Cefuroxime Axetil | 61 | 49 |
| Ondansetron Odt | Ondansetron | 57 | 40 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | 13 |
| Tramadol Hcl | Tramadol Hcl | 55 | 24 |
| Nifedipine Er | Nifedipine | 54 | 13 |
| Xarelto | Rivaroxaban | 53 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 21 |
| Amoxicillin | Amoxicillin | 51 | 35 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 46 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 14 |
| Mirtazapine | Mirtazapine | 45 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 12 |
| Fluconazole | Fluconazole | 43 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 25 |
| Atenolol | Atenolol | 41 | 14 |
| Methylprednisolone | Methylprednisolone | 41 | 41 |
| Jardiance | Empagliflozin | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 23 |
| Levofloxacin | Levofloxacin | 38 | 30 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Cefdinir | Cefdinir | 36 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Glipizide | Glipizide | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 28 |
| Naproxen | Naproxen | 31 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 22 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Nystatin | Nystatin | 28 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 26 | 21 |
| Lactulose | Lactulose | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | 12 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 16 |
| Lovastatin | Lovastatin | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Silodosin | Silodosin | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Humulin R | Insulin Regular, Human | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Dexilant | Dexlansoprazole | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $165.24 · 9 records | Axsome Therapeutics, Inc. | Auvelity, CAPLYTA, Cologuard Collection Kit, JARDIANCE, QULIPTA, UBRELVY, VOQUEZNA, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error